Page last updated: 2024-10-15

capromab pendetide

Description

Capromab Pendetide: an (111)Indium-labeled IgG antibody against a prostate specific membrane antigen (PSMA); used in the evaluation of metastatic involvement in prostate cancer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135509147
SCHEMBL ID2315499
MeSH IDM0265650

Synonyms (9)

Synonym
145464-28-4
guanosine-3',5'-diphosphate
capromab pendetide
[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate
SCHEMBL2315499
guanosine 3',5'-diphosphate
guanosine 3',5'-bis(dihydrogen phosphate)
Q27464412
[(2r,3s,4r,5r)-5-(2-amino-6-oxo-1h-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate

Research Excerpts

Overview

Capromab pendetide (ProstaScint) is an indium In 111 ((111)In)-labeled monoclonal antibody to prostate-specific membrane antigen (PSMA) used to image prostate cancer.

ExcerptReference
"Capromab Pendetide is a technically demanding procedure best performed and interpreted at sites with experience and expertise."( Capromab Pendetide imaging of prostate cancer.
Haseman, MK; Polascik, TJ; Rosenthal, SA, 2000
)
"Capromab pendetide (ProstaScint) is an indium In 111 ((111)In)-labeled monoclonal antibody to prostate-specific membrane antigen (PSMA) used to image prostate cancer. "( Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
Haseman, MK; Polascik, TJ; Rosenthal, SA, 2001
)

Effects

ExcerptReference
"The capromab pendetide scan has a low positive predictive value in patients with positive elsewhere uptake and the 4-year bRFS was similar to that for those who did not exhibit positive elsewhere uptake. "( Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
Campbell, S; Dillehay, G; Flanigan, R; Khan, U; Lo, SS; Mohideen, N; Nagda, SN; Wagner, R, 2007
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (89)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's22 (24.72)18.2507
2000's55 (61.80)29.6817
2010's12 (13.48)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (13.83%)5.53%
Reviews18 (19.15%)6.00%
Case Studies18 (19.15%)4.05%
Observational0 (0.00%)0.25%
Other45 (47.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]